Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of $0.31, $0.01 better than the analyst estimate of $0.30. Revenue for the quarter came in at $2.98 million versus the consensus estimate of $500 thousand.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.